论文部分内容阅读
（目的）评价CHEP方案和B-CHOP方案治疗非霍奇金淋巴瘤（NHL）的疗效和毒性。（方法）1990年6月至1998年4月应用CHEP方案（环磷酰胺、阿霉素、足叶乙甙、强的松）或B-CHOP方案（平阳毒素、环磷酰胺、阿霉素、长春新碱、强的松）治疗NHL30例，随机分组，每组15例。疗效和毒性用卡方检验。（结果）CHEP组有效率86．6％（13／15），其中初治6例中，完全缓解（CR）5例；B-CHOP组有效率73．3％（11／15），初治10例中，CR5例（5／10）。随访至1998年4月底，CHEP组存活10例，B-CHOP组存活9例，中位生存期为25个月和19个月。初治CR者，一年无病生存（DFS）率两组分别为83．3％和Zo％，差异有显著性（P＜0．05），2～5年DFS率差异无显著性（P＞0．05）。两组毒性均可耐受。（结论）CHEP治疗NHL，初治一年DFS率显著优于BCHOP组（P＜0．05），且CHEP组无发热反应，无末梢神经毒性。
(Objective) To evaluate the efficacy and toxicity of the CHEP regimen and the B-CHOP regimen in the treatment of non-Hodgkin’s lymphoma (NHL). (Methods) CHEP (Cyclophosphamide, Adriamycin, Etoposide, Prednisone) or B-CHOP (Cytotoxin, Cyclophosphamide, Doxorubicin) was used between June 1990 and April 1998. Nine cases of NHL were treated with vincristine and prednisone. Randomly divided into groups. There were 15 cases in each group. Efficacy and toxicity were tested using the chi-square test. (Results) The effective rate in the CHEP group was 86.6% (13/15), of which 6 cases were completely resolved (CR) in the initial treatment; 73.3% (11/15) were effective in the B-CHOP group. Of the 10 cases, 5 were CR (5/10). At the end of April 1998, CHEP group survived in 10 cases, and B-CHOP group survived in 9 cases. The median survival time was 25 months and 19 months. In the newly diagnosed CR patients, the disease-free survival (DFS) rate was 83.3% and Zo% in the two groups respectively, the difference was significant (P<0.05), and there was no significant difference in DFS rate between 2 and 5 years (P). >0.05). Both groups can tolerate toxicity. (Conclusion) CHEP treatment of NHL, the initial year DFS rate was significantly better than BCHOP group (P <0.05), and CHEP group no fever reaction, no peripheral nerve toxicity.